Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Jieyu prescription refers to a category of traditional Chinese medicine (TCM) formulations designed to alleviate depression. The specific "self-designed Jieyu prescription" mentioned in the clinical trial context is being investigated by Wenzhou Hospital of Traditional Chinese Medicine for the treatment of post-stroke depression (PSD). Administered orally, its therapeutic effects are believed to involve the modulation of the gut microbiota, influencing the gut-brain axis, and potentially inhibiting neuroinflammation and regulating the hypothalamic-pituitary-adrenal (HPA) axis. Other proposed mechanisms for various Jieyu formulations include increasing levels of neurotransmitters like serotonin and GABA, and neurotrophic factors such as BDNF.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Jieyu prescription.